Assessment of Allergic Reaction of Covid-19 Vaccination among Malaysian Adults: A Cross-sectional Study
Main Article Content
Abstract
Introduction: The AstraZeneca, Pfizer-BioNTech, and Sinovac-CoronaVac vaccines presented side-effects in their clinical trials thus, this study aims to assess the allergic reaction post-Covid-19 vaccination among Malaysian adults. Materials and methods: A cross-sectional study was performed using simple random sampling via social media platforms from March 2022 to June 2022. The study included an online questionnaire regarding sociodemographic, vaccine and allergy reactions. The inclusion criteria were Malaysian adults aged above 18 years old. Pregnant women, lactating women and individuals with comorbidities were included. The exclusion criteria were children aged below 18 years old and non-Malaysians. Estimated sample size using Cochran formula is 385 respondents (95% confidence interval, 5% margin error and 50% assumption of population proportion). Results: The response rate was 81% (315 respondents) with no previous history of Covid-19 infection and based on their first vaccination. Most of the respondents’ age was between 21 to 30 and female (76%). Most respondents received Pfizer-BioNTech (48.9%), followed by Sinovac-CoronaVac (27.4%), and AstraZeneca (23.6%). Few respondents (7.59%) who received mRNA-based vaccines had mild allergic reactions, followed by the viral vector, and inactivated virus vaccines. Overall, 14.5% of respondents had mild allergic reactions characterized by superficial, and respiratory symptoms, while 0.28% experienced severe symptoms. Few respondents experienced allergic reactions which were similar to those reported in clinical trials. Conclusion: The most common allergic reaction was shortness of breath and wheezing. There is no significant association between type of vaccine and allergy (p > 0.05), further research is still needed to investigate long-term effects of Covid-19 vaccination.
Downloads
Article Details
References
Lotfi M, Hamblin MR, Rezaei N. Covid-19: Transmission, Prevention, and Potential Therapeutic Opportunities. *Clin Chim Acta*. 2020;508:254–66. doi:10.1016/j.cca.2020.05.044.
World Health Organization. WHO Director-General's opening remarks at the media briefing on Covid-19—11 March 2020. [Internet]. 2020 [cited 2024 May 26]. Available from: [https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020](https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020).
U.S. Food and Drug Administration. FDA Takes Key Action in Fight Against Covid-19 by Issuing Emergency Use Authorization for First Covid-19 Vaccine. [Internet]. 2020 [cited 2024 May 26]. Available from: [https://www.fda.gov/news-events/press-announcements/fda-takes-key-action-fight-against-covid-19-issuing-emergency-use-authorization-first-covid-19](https://www.fda.gov/news-events/press-announcements/fda-takes-key-action-fight-against-covid-19-issuing-emergency-use-authorization-first-covid-19).
Meo SA, Bukhari IA, Akram J, Meo AS, Klonoff DC. Covid-19 Vaccines: Comparison of Biological, Pharmacological Characteristics and Adverse Effects of Pfizer/BioNTech and Moderna Vaccines. *Eur Rev Med Pharmacol Sci*. 2021;25(3):1663–79. doi:10.26355/eurrev_202102_24877.
Beatty AL, Peyser ND, Butcher XE, Cocohoba JM, Lin F, Olgin JE, Pletcher MJ, Marcus GM. Analysis of Covid-19 Vaccine Type and Adverse Effects Following Vaccination. *JAMA Netw Open*. 2021;12:e2140364. doi:10.1001/jamanetworkopen.2021.40364.
Cabanillas B, Novak N. Allergy to Covid-19 Vaccines: A Current Update. *Allergol Int*. 2021;7(3):313–8. doi:10.1016/j.alit.2021.04.003.
Ministry of Health Malaysia. Clinical Guidelines on Covid-19 Vaccination in Malaysia. 4th ed. Putrajaya: Ministry of Health Malaysia; 2021.
Feinmann J. Covid-19: Global Vaccine Production Is a Mess and Shortages Are Down to More Than Just Hoarding. *BMJ*. 2021;375:n2375. doi:10.1136/bmj.n2375.
Kaur SP, Gupta V. Covid-19 Vaccine: A Comprehensive Status Report. *Virus Res*. 2020;288:198114. doi:10.1016/j.virusres.2020.198114.
Media AHC. FDA Approves Pfizer Vaccine for Covid-19: Designated Groups First, but Approval Is for All 16 Years of Age and Older. *Hosp Infect Control Prev*. 2021;48(1):1–3.
Chen G, Zhang Y, Wu K, Jin T, Peng C, Jiang Q, et al. Safety, tolerability, pharmacokinetics, and immunogenicity of JMB2002—an antibody against Covid-19: a phase 1 clinical trial in healthy Chinese adults. *BMC Infect Dis*. 2023;23(1):1–9. doi:10.1186/s12879-023-08341-6.
Walter G, Jeimy S, Liddy C, Guglani S, Ellis AK, Blair A, et al. Utility of eConsults for Covid-19 vaccine-related concerns in Ontario: a cross-sectional analysis. *Allergy Asthma Clin Immunol*. 2023;19(1):1–9. doi:10.1186/s13223-023-00789-0.
Hatmal MM, Mohammad AI, Al-Hatamleh AN, Hatmal OM, Dina MA, Tamadur MO, Mohamud R. Side Effects and Perceptions Following Covid-19 Vaccination in Jordan: A Randomized, Cross-Sectional Study Implementing Machine Learning for Predicting Severity of Side Effects. *Vaccines*. 2021;9(6):556. doi:10.3390/vaccines9060556.
Sultana A, Shahriar S, Tahsin MR, Mim SR, Fatema KR, Saha A, et al. A Retrospective Cross-Sectional Study Assessing Self-Reported Adverse Events Following Immunization (AEFI) of the Covid-19 Vaccine in Bangladesh. *Vaccines*. 2021;9(10):1090. doi:10.3390/vaccines9101090.
Lau JFW, Woon YL, Leong CT, Teh HS. Factors Influencing Acceptance of the Covid-19 Vaccine in Malaysia: A Web-Based Survey. *Osong Public Health Res Perspect*. 2021;12(6):361–73. doi:10.24171/j.phrp.2021.0085.
Lai X, Zhu H, Wang J, Huang Y, Jing R, Lyu Y, et al. Public Perceptions and Acceptance of Covid-19 Booster Vaccination in China: A Cross-Sectional Study. *Vaccines*. 2021;9(12):1461. doi:10.3390/vaccines9121461.
Turk VE. Anaphylaxis Associated with the mRNA Covid-19 Vaccines: Approach to Allergy Investigation. *Clin Immunol*. 2021;227:108748. doi:10.1016/j.clim.2021.108748.
Nittner-Marszalska M, Rosiek-Biegus M, Kopeć A, Pawłowicz R, Kosińska M, Łata A, et al. Pfizer-BioNTech Covid-19 Vaccine Tolerance in Allergic versus Non-Allergic Individuals. *Vaccines*. 2021;9(6):553. doi:10.3390/vaccines9060553.
Ab Rahman N, Lim MT, Lee FY, Ong SM, Peariasamy KM, Sivasampu S. A Case-Based Monitoring Approach to Evaluate Safety of Covid-19 Vaccines in a Partially Integrated Health Information System: A Study Protocol. *Front Pharmacol*. 2022;13:834940. doi:10.3389/fphar.2022.834940.
Almohaya AM, Qari F, Zubaidi GA, Alnajim N, Moustafa K, Alshabi MM, et al. Early Solicited Adverse Events Following the BNT162b2 mRNA Vaccination, a Population Survey from Saudi Arabia. *Prev Med Rep*. 2021;24:101595. doi:10.1016/j.pmedr.2021.101595.
Ab Rahman N, Lim MT, Lee FY, Lee SC, Ramli A, Saharudin SN, et al. Risk of Serious Adverse Events after the BNT162b2, CoronaVac, and ChAdOx1 Vaccines in Malaysia: A Self-Controlled Case Series Study. *Vaccine*. 2022;40(32):4394–402. doi:10.1016/j.vaccine.2022.05.075.
Desai AP, Desai AP, Loomis GJ. Relationship between Pre-Existing Allergies and Anaphylactic Reactions Post mRNA Covid-19 Vaccine Administration. *Vaccine*. 2021;39(32):4407–9. doi:10.1016/j.vaccine.2021.06.058.
Al Khames Aga QA, Alkhaffaf WH, Hatem TH, Nassir KF, Batineh Y, Dahham AT, et al. Safety of Covid-19 Vaccines. *J Med Virol*. 2021;93(12):6588–94. doi:10.1002/jmv.27214.
Risma KA, Edwards KM, Hummell DS, Little FC, Norton AE, Stallings A, et al. Potential Mechanisms of Anaphylaxis to Covid-19 mRNA Vaccines. *J Allergy Clin Immunol*. 2021;147(6):2075–82.e2. doi:10.1016/j.jaci.2021.04.002.
Kahraman FC, Erdoğan SS, Aktaş ND, Albayrak H, Türkmen D, Borlu M, et al. Cutaneous reactions after Covid-19 vaccination in Turkey: a multicenter study. *J Cosmet Dermatol*. 2022;21(9):3692–703. doi:10.1111/jocd.15209.
Idris NA, Yusof NA, Yunus NI, Daud N, Juhari SN, Mat Hassan N, et al. The Adverse Effects After Covid-19 Vaccination and Its Determinants among Adults in Kuala Terengganu. *Asian J Med Biomed*. 2023;7(1):27–38. doi:10.37231/ajmb.2023.7.1.597.
Temiz SA, Abdelmaksoud A, Wollina U, Kutlu O, Dursun R, Patil A, et al. Cutaneous and allergic reactions due to Covid-19 vaccinations: a review. *J Cosmet Dermatol*. 2022;21(1):4–12. doi:10.1111/jocd.14613.
Kutlu Ö, Temiz SA. Similarity between cutaneous reactions due to SARS-CoV-2 and its vaccinations. *Future Virol*. 2022;17(12):845–8. doi:10.2217/fvl-2021-0357.
Krishna MT, Subramanian A, Adderley NJ, Zemedikun DT, Gkoutos GV, Nirantharakumar K. Allergic diseases and long-term risk of autoimmune disorders: longitudinal cohort study and cluster analysis. *Eur Respir J*. 2019;54(5). doi:10.1183/13993003.00476-2019.
Jmor S, Yip V. Cutaneous reactions secondary to Covid-19 vaccination. *Prescriber*. 2023;34(8–9):13–8. doi:10.1002/PSB.2085.